DOCSLIB.ORG

Large-Scale Serum Protein Biomarker Discovery in Duchenne Muscular Dystrophy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Large-Scale Serum Protein Biomarker Discovery in Duchenne Muscular Dystrophy Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Yetrib Hathouta, Edward Brodyb, Paula R. Clemensc,d, Linda Cripee, Robert Kirk DeLisleb, Pat Furlongf, Heather Gordish- Dressmana, Lauren Hachea, Erik Henricsong, Eric P. Hoffmana, Yvonne Monique Kobayashih, Angela Lortsi, Jean K. Mahj, Craig McDonaldg, Bob Mehlerb, Sally Nelsonk, Malti Nikradb, Britta Singerb, Fintan Steeleb, David Sterlingb, H. Lee Sweeneyl, Steve Williamsb, and Larry Goldb,1 aResearch Center for Genetic Medicine, Children’s National Medical Center, Washington, DC 20012; bSomaLogic, Inc., Boulder, CO 80301; cNeurology Service, Department of Veteran Affairs Medical Center, Pittsburgh, PA 15240; dUniversity of Pittsburgh, Pittsburgh, PA 15213; eThe Heart Center, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH 15213; fParent Project Muscular Dystrophy, Hackensack, NJ 07601; gDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Davis, CA 95618; hDepartment of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN 46202; iThe Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229; jDepartment of Pediatrics, University of Calgary, Alberta Children’s Hospital, Calgary, AB, Canada T3B 6A8; kDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO 80045; and lDepartment of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL 32610 Contributed by Larry Gold, April 29, 2015 (sent for review March 6, 2015; reviewed by Allan Jacobson) Serum biomarkers in Duchenne muscular dystrophy (DMD) may minidystrophins, up-regulation of utrophin to compensate for provide deeper insights into disease pathogenesis, suggest new the missing dystrophin, and many others (17). Pharmacological therapeutic approaches, serve as acute read-outs of drug effects, strategies in development include dissociative steroid drugs, and be useful as surrogate outcome measures to predict later clin- which offer the potential of greater efficacy and lesser side ef- ical benefit. In this study a large-scale biomarker discovery was fects (18), other anti-inflammatory therapies, and effectors of performed on serum samples from patients with DMD and age- signaling pathways (19). The current primary clinical endpoint matched healthy volunteers using a modified aptamer-based pro- used for determining efficacy in the majority of these therapeutic teomics technology. Levels of 1,125 proteins were quantified in approaches for ambulatory boys with DMD is the “six-minute serum samples from two independent DMD cohorts: cohort 1 (The ” – ’ walk test (20, 21), although it is not ideal (22). Parent Project Muscular Dystrophy Cincinnati Children s Hospital Blood provides a circulating protein representation of all body Medical Center), 42 patients with DMD and 28 age-matched normal tissue in both normal and pathological conditions, and serum volunteers; and cohort 2 (The Cooperative International Neuromus- proteins are emerging as useful biomarkers for diagnosis and cular Research Group, Duchenne Natural History Study), 51 patients prognosis of a growing number of diseases (23, 24). Mass spec- with DMD and 17 age-matched normal volunteers. Forty-four pro- teins showed significant differences that were consistent in both trometry (MS)-based proteomic screens recently have proved cohorts when comparing DMD patients and healthy volunteers at successful at de novo biomarker identification in DMD (25). a 1% false-discovery rate, a large number of significant protein However, verification and validation of MS-discovered serum changes for such a small study. These biomarkers can be classified biomarkers remain challenging (24). Other approaches, such as by known cellular processes and by age-dependent changes in pro- multiplexed antibody or aptamer-based assays, are being con- tein concentration. Our findings demonstrate both the utility of this sidered for proteome screens because of their potential for unbiased biomarker discovery approach and suggest potential new higher throughput and better sensitivity, which may help overcome diagnostic and therapeutic avenues for ameliorating the burden of the validation challenges of identified biomarkers. For example, a DMD and, we hope, other rare and devastating diseases. Significance proteomics | muscular dystrophy | biomarkers | SOMAscan | SOMAmer Duchenne muscular dystrophy (DMD) is a rare and devastating here is an urgent need for a reliable surrogate biomarker or muscle disease caused by mutations in the X-linked DMD gene Tset of biomarkers for Duchenne muscular dystrophy (DMD), (which encodes the dystrophin protein). Serum biomarkers hold ideally based on readily accessible and measurable molecules (1). significant potential as objective phenotypic measures of DMD DMD is a severe form of myopathy with an incidence of about 1 disease state, as well as potential measures of pharmacological in 3,600–9,337 boys worldwide (2, 3), and is a result of different effects of and response to therapeutic interventions. Here we types of mutations in the X-linked DMD gene that abolish the describe a proteomics approach to determine serum levels of expression and biological activity of dystrophin, an essential pro- 1,125 proteins in 93 DMD patients and 45 controls. The study tein for muscle-fiber plasma membrane integrity and myofiber identified 44 biomarkers that differed significantly between function (4, 5). Clinically, the disease is characterized by pro- patients and controls. These data are being made available to gressive muscle wasting, leading to loss of ambulation by 8–15 y DMD researchers and clinicians to accelerate the search for new of age and early death from complications from respiratory, diagnostic, prognostic, and therapeutic approaches. orthopedic, and cardiac problems (2, 6). Several current drug-development programs are focused on Author contributions: Y.H., P.R.C., L.C., P.F., L.H., E.H., E.P.H., C.M., S.N., H.L.S., and L.G. slowing or preventing the progressive muscle loss in DMD either designed research; L.C., H.G.-D., E.H., A.L., and J.K.M. performed research; Y.H., E.B., R.K.D., Y.M.K., B.M., S.N., M.N., B.S., F.S., D.S., H.L.S., S.W., and L.G. analyzed data; and Y.H., E.B., in conjunction with the standard of care treatment or as stand- R.K.D., Y.M.K., S.N., F.S., D.S., H.L.S., and L.G. wrote the paper. alone therapies. Standard of care is currently chronic high-dose Reviewers included: A.J., University of Massachusetts Medical School. – glucocorticoids, which are able to prolong ambulation by 3 4y Conflict of interest statement: L.G. is the founder and a stakeholder in SomaLogic, Inc; (7, 8) and slow disease progression, but are associated with a E.B., R.K.D., B.M., M.N., B.S., F.S., D.S., and S.W. are employees and stakeholders in Soma- significant array of side effects (2, 6, 9, 10). Promising thera- Logic, Inc.; Y.M.K. has been affiliated with the Eli Lilly and Co. since October 2012. peutic approaches for DMD include restoring expression of the Freely available online through the PNAS open access option. – 1 dystrophin gene via exon-skipping strategies (11 13), viral-based To whom correspondence should be addressed. Email: [email protected]. SCIENCES gene therapies (14, 15), and nonsense suppression/read-through This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. strategies (16). Other genetic approaches include delivering 1073/pnas.1507719112/-/DCSupplemental. APPLIED BIOLOGICAL www.pnas.org/cgi/doi/10.1073/pnas.1507719112 PNAS | June 9, 2015 | vol. 112 | no. 23 | 7153–7158 Downloaded by guest on September 29, 2021 recent study using an antibody-based array against 384 target results. Our standard quality-control protocols detected no sig- proteins identified 11 protein biomarkers of disease across dif- nificant difference in the samples from the two cohorts. ferent muscular dystrophies from patient samples gathered Serum samples were tested using the SOMAscan protein from four different clinical sites (26). In addition, a modified biomarker discovery assay (SomaLogic), which detects 1,125 aptamer-based technology (the SOMAscan assay) is emerging as proteins simultaneously using 65 μL of serum. At a 1% false- another highly sensitive and multiplexed assay for biomarker discovery rate (FDR) (Materials and Methods), based on SOMAscan discovery and validation (27–29). Based on novel reagents (Slow assay data from a total of 93 DMD patients and 45 age-matched Off-rate Modified Aptamers, or SOMAmer reagents) that rec- controls from the two cohorts, we identified 44 proteins that ognize specific conformational epitopes of native 3D proteins consistently differed in the serum in both cohorts when comparing with high specificity and high sensitivity (30–32), the SOMAscan DMD patients vs. controls. The UniProt names and a measure assay measures levels of 1,125 analytes in only 65 μL of serum of differential expression [the signed Kolmogorov–Smirnov (KS) over a wide dynamic range (>8 logs of concentration). Because distance] for these 44 proteins in each cohort are shown in Table 1, the SOMAscan assay relies on the availability of the protein along with an indicator of each protein’s known enrichment in epitopes (i.e., the epitopes are not blocked by other protein muscle tissue. The entire 1,125 protein SOMAscan assay results binding, posttranslational modifications, and so forth),
Load more

Recommended publications
  • FLNC Pathogenic Variants in Patients with Cardiomyopathies
    FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations Flavie Ader, Pascal de Groote, Patricia Réant, Caroline Rooryck-Thambo, Delphine Dupin-Deguine, Caroline Rambaud, Diala Khraiche, Claire Perret, Jean-François Pruny, Michèle Mathieu-dramard, et al. To cite this version: Flavie Ader, Pascal de Groote, Patricia Réant, Caroline Rooryck-Thambo, Delphine Dupin-Deguine, et al.. FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations. Clinical Genetics, Wiley, 2019, 96 (4), pp.317-329. 10.1111/cge.13594. hal-02268422 HAL Id: hal-02268422 https://hal-normandie-univ.archives-ouvertes.fr/hal-02268422 Submitted on 29 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. FLNC pathogenic variants in patients with cardiomyopathies Prevalence and genotype-phenotype correlations Running Title : FLNC variants genotype-phenotype correlation Flavie Ader1,2,3, Pascal De Groote4, Patricia Réant5, Caroline Rooryck-Thambo6, Delphine Dupin-Deguine7, Caroline Rambaud8, Diala Khraiche9, Claire Perret2, Jean Francois Pruny10, Michèle Mathieu Dramard11, Marion Gérard12, Yann Troadec12, Laurent Gouya13, Xavier Jeunemaitre14, Lionel Van Maldergem15, Albert Hagège16, Eric Villard2, Philippe Charron2, 10, Pascale Richard1, 2, 10. Conflict of interest statement: none declared for each author 1.
    [Show full text]
  • Genetic Variation Screening of TNNT2 Gene in a Cohort of Patients with Hypertrophic and Dilated Cardiomyopathy
    Physiol. Res. 61: 169-175, 2012 https://doi.org/10.33549/physiolres.932157 Genetic Variation Screening of TNNT2 Gene in a Cohort of Patients With Hypertrophic and Dilated Cardiomyopathy M. JÁCHYMOVÁ1, A. MURAVSKÁ1, T. PALEČEK2, P. KUCHYNKA2, H. ŘEHÁKOVÁ1, S. MAGAGE2, A. KRÁL2, T. ZIMA1, K. HORKÝ2, A. LINHART2 1Institute of Clinical Chemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic, 2Second Department of Internal Medicine – Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic Received February 1, 2011 Accepted October 17, 2011 On-line January 31, 2012 Summary Introduction Mutations in troponin T (TNNT2) gene represent the important part of currently identified disease-causing mutations in Cardiomyopathies are generally defined as hypertrophic (HCM) and dilated (DCM) cardiomyopathy. The aim myocardial disorders in which the heart muscle is of this study was to analyze TNNT2 gene exons in patients with structurally and functionally abnormal, in the absence of HCM and DCM diagnosis to improve diagnostic and genetic coronary artery disease, hypertension, valvular disease consultancy in affected families. All 15 exons and their flanking and congenital heart disease sufficient to cause the regions of the TNNT2 gene were analyzed by DNA sequence observed myocardial abnormality (Elliott et al. 2008). analysis in 174 patients with HCM and DCM diagnosis. We According to the morphological and functional phenotype identified genetic variations in TNNT2 exon regions in 56 patients the diagnosis of hypertrophic and dilated cardiomyopathy and genetic variations in TNNT2 intron regions in 164 patients.
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • TNNI3 Gene Troponin I3, Cardiac Type
    TNNI3 gene troponin I3, cardiac type Normal Function The TNNI3 gene provides instructions for making a protein called cardiac troponin I, which is found solely in the heart (cardiac) muscle. Cardiac troponin I is one of three proteins that make up the troponin protein complex in cardiac muscle cells. The troponin complex is associated with a structure called the sarcomere, which is the basic unit of muscle contraction. Sarcomeres are made up of thick and thin filaments. The overlapping thick and thin filaments attach (bind) to each other and release, which allows the filaments to move relative to one another so that muscles can contract. The troponin complex, along with calcium, helps regulate tensing (contraction) of cardiac muscle. For the heart to beat normally, cardiac muscle must contract and relax in a coordinated way. Cardiac troponin I helps to coordinate contraction of the heart. When calcium levels are low, the troponin complex binds to the thin filament. This binding blocks the interaction between the thick and thin filaments that is needed for muscle contraction. An increase in calcium levels causes structural changes in another troponin complex protein called troponin C, which then triggers the troponin complex to detach from the thin filament, allowing the heart muscle to contract. Health Conditions Related to Genetic Changes Familial hypertrophic cardiomyopathy Mutations in the TNNI3 gene can cause familial hypertrophic cardiomyopathy, a condition characterized by thickening (hypertrophy) of the cardiac muscle. TNNI3 gene mutations are found in less than 5 percent of people with this condition. Although some people with hypertrophic cardiomyopathy have no obvious health effects, all affected individuals have an increased risk of heart failure and sudden death.
    [Show full text]
  • Acemannan Stimulates Bone Sialoprotein, Osteocalcin, Osteopon- Tin and Osteonectin Expression in Periodontal Ligament Cells in V
    Original Article บ ท วิ ท ย า ก า ร Acemannan Stimulates Bone Sialoprotein, Osteocalcin, Osteopon- tin and Osteonectin Expression in Periodontal Ligament Cells in Vitro Pintu-on Chantarawaratit1,2,4, Polkit Sangvanich3 and Pasutha Thunyakitpisal2,4 1Department of Orthodontics, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand 2Dental Biomaterials Program, Graduate School, Chulalongkorn University, Bangkok, Thailand 3Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand 4Research Unit of Herbal Medicine and Natural Products of Dental Application, Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand Correspondence to: Pasutha Thunyakitpisal, Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, 34, Henri-Dunant Rd, Patumwan, Bangkok 10330, Thailand Email: [email protected] Abstract The periodontium is composed of both soft and hard tissues, thus hard tissue regeneration is one of the most important processes in periodontal regeneration. Bone sialoprotein, osteocalcin, osteopontin and osteonectin are non- collagenous matrix proteins which play vital roles in the mineralization of hard tissue. Recent studies have demonstrated that acemannan, a polysaccharide extracted from Aloe vera gel, upregulated the expression of proteins involved in hard tissue regeneration. This study investigated effect of acemannan on bone sialoprotein, osteocalcin, osteopontin and osteonectin expression in human periodontal ligament cells. Primary periodontal ligament cells were isolated from impacted third molars and then treated with acemannan in vitro. The mRNA expression of bone sialoprotein and osteocalcin and the protein levels of osteopontin and osteonectin were determined using reverse transcription-polymerase chain reaction and western blot analysis, respectively. One-way analysis of variance and Dunnett multiple comparisons were performed to analyze the data.
    [Show full text]
  • Novel Pathogenic Variants in Filamin C Identified in Pediatric Restrictive Cardiomyopathy
    Novel pathogenic variants in filamin C identified in pediatric restrictive cardiomyopathy Jeffrey Schubert1, 2, Muhammad Tariq3, Gabrielle Geddes4, Steven Kindel4, Erin M. Miller5, and Stephanie M. Ware2. 1 Department of Molecular Genetics, Microbiology, and Biochemistry, University of Cincinnati College of Medicine, Cincinnati, OH; 2 Departments of Pediatrics and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN; 3 Faculty of Applied Medical Science, University of Tabuk, Tabuk, Kingdom of Saudi Arabia; 4Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 5Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. Correspondence: Stephanie M. Ware, MD, PhD Department of Pediatrics Indiana University School of Medicine 1044 W. Walnut Street Indianapolis, IN 46202 Telephone: 317 274-8939 Email: [email protected] Grant Sponsor: The project was supported by the Children’s Cardiomyopathy Foundation (S.M.W.), an American Heart Association Established Investigator Award 13EIA13460001 (S.M.W.) and an AHA Postdoctoral Fellowship Award 12POST10370002 (M.T.). ___________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schubert, J., Tariq, M., Geddes, G., Kindel, S., Miller, E. M., & Ware, S. M. (2018). Novel pathogenic variants in filamin C identified in pediatric restrictive cardiomyopathy. Human Mutation, 0(ja). https://doi.org/10.1002/humu.23661 Abstract Restrictive cardiomyopathy (RCM) is a rare and distinct form of cardiomyopathy characterized by normal ventricular chamber dimensions, normal myocardial wall thickness, and preserved systolic function. The abnormal myocardium, however, demonstrates impaired relaxation. To date, dominant variants causing RCM have been reported in a small number of sarcomeric or cytoskeletal genes, but the genetic causes in a majority of cases remain unexplained especially in early childhood.
    [Show full text]
  • CHAPTER 41 Target Genes: Bone Proteins 719
    CHAPTER 41 Target Genes: Bone Proteins 719 45. Bellows CG, Reimers SM, Heersche JN 1999 Expression of 61. Price PA, Williamson MK, Lothringer JW 1981 Origin of the mRNAs for type-I collagen, bone sialoprotein, osteocalcin, vitamin K-dependent bone protein found in plasma and its and osteopontin at different stages of osteoblastic differentia- clearance by kidney and bone. J Biol Chem 256:12760–12766. tion and their regulation by 1,25-dihydroxyvitamin D3. Cell 62. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Tissue Res 297:249–259. Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, 46. Broess M, Riva A, Gerstenfeld LC 1995 Inhibitory effects of Karsenty G 1996 Increased bone formation in osteocalcin- 1,25(OH)2 vitamin D3 on collagen type I, osteopontin, and deficient mice. Nature 382:448–452. osteocalcin gene expression in chicken osteoblasts. J Cell 63. Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Biochem 57:440–451. Zambonin G, Baldini N, Vergnaud P, Delmas PD, Zallone AZ 47. Yoon K, Buenaga R, Rodan GA, Prince CW, Butler WT 1994 Osteocalcin induces chemotaxis, secretion of matrix pro- 1987 Tissue specificity and developmental expression of teins, and calcium-mediated intracellular signaling in human rat osteopontin. Biochem Biophys Res Commun 148: osteoclast-like cells. J Cell Biol 127:1149–1158. 1129–1136. 64. Watts NB 1999 Clinical utility of biochemical markers of bone 48. Beresford JN, Joyner CJ, Devlin C, Triffitt JT 1994 The effects remodeling. Clin Chem 45:1359–1368. of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic 65.
    [Show full text]
  • Troponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics
    International Journal of Molecular Sciences Review Troponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics Martijn van de Locht , Tamara C. Borsboom, Josine M. Winter and Coen A. C. Ottenheijm * Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Location VUmc, 1081 HZ Amsterdam, The Netherlands; [email protected] (M.v.d.L.); [email protected] (T.C.B.); [email protected] (J.M.W.) * Correspondence: [email protected]; Tel.: +31-(0)-20-444-8123 Abstract: The troponin complex is a key regulator of muscle contraction. Multiple variants in skeletal troponin encoding genes result in congenital myopathies. TNNC2 has been implicated in a novel congenital myopathy, TNNI2 and TNNT3 in distal arthrogryposis (DA), and TNNT1 and TNNT3 in nemaline myopathy (NEM). Variants in skeletal troponin encoding genes compromise sarcomere function, e.g., by altering the Ca2+ sensitivity of force or by inducing atrophy. Several potential therapeutic strategies are available to counter the effects of variants, such as troponin activators, introduction of wild-type protein through AAV gene therapy, and myosin modulation to improve muscle contraction. The mechanisms underlying the pathophysiological effects of the variants in skeletal troponin encoding genes are incompletely understood. Furthermore, limited knowledge is available on the structure of skeletal troponin. This review focusses on the physiology of slow and fast skeletal troponin and the pathophysiology of reported variants in skeletal troponin encoding genes. A better understanding of the pathophysiological effects of these variants, together with enhanced knowledge regarding the structure of slow and fast skeletal troponin, will direct the development of Citation: van de Locht, M.; treatment strategies.
    [Show full text]
  • Method for Predicting the Occurence of Lung Metastasis in Breast Cancer Patients
    (19) TZZ ¥ __T (11) EP 2 253 721 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 24.11.2010 Bulletin 2010/47 C12Q 1/68 (2006.01) (21) Application number: 10175619.5 (22) Date of filing: 26.02.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Lidereau, Rosette HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT 92230, Gennevilliers (FR) RO SE SI SK TR • Driouch, Keltouma Designated Extension States: 93260, Les Lilas (FR) AL BA MK RS • Landemaine, Thomas 92100, Boulogne-Billancourt (FR) (30) Priority: 26.02.2007 EP 07300823 (74) Representative: Catherine, Alain et al (62) Document number(s) of the earlier application(s) in Cabinet Harlé & Phélip accordance with Art. 76 EPC: 7 rue de Madrid 08709219.3 / 2 115 170 75008 Paris (FR) (71) Applicants: Remarks: • INSERM (Institut National de la Santé et de la This application was filed on 07-09-2010 as a Recherche Medicale) divisional application to the application mentioned 75013 Paris (FR) under INID code 62. • Centre Rene Huguenin 92210 Saint-Cloud (FR) (54) Method for predicting the occurence of lung metastasis in breast cancer patients (57) The present invention relates to the prognosis tasis in one or more tissue or organ of patients affected of the progression of breast cancer in a patient, and more with a breast cancer. particularly to the prediction of the occurrence of metas- EP 2 253 721 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 253 721 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to the prognosis of the progression of breast cancer in a patient, and more particularly to the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a breast cancer.
    [Show full text]
  • 2598 Biomineralization of Bone: a Fresh View of the Roles of Non-Collagen
    [Frontiers in Bioscience 16, 2598-2621, June 1, 2011] Biomineralization of bone: a fresh view of the roles of non-collagenous proteins Jeffrey Paul Gorski1 1Center of Excellence in the Study of Musculoskeletal and Dental Tissues and Dept. of Oral Biology, Sch. Of Dentistry, Univ. of Missouri-Kansas City, Kansas City, MO 64108 TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Proposed mechanisms of mineral nucleation in bone 3.1. Biomineralization Foci 3.2. Calcospherulites 3.3. Matrix vesicles 4. The role of individual non-collagenous proteins 4.1. Bone Sialoprotein 4.2. Noggin 4.3. Chordin 4.4. Osteopontin 4.5. Osteopontin, bone sialoprotein, and DMP1 form individual complexes with MMPs 4.6. Bone acidic glycoprotein-75 4.7. Dentin matrix protein1 4.8. Osteocalcin 4.9. Fetuin (alpha2HS-glycoprotein) 4.10. Periostin 4.11. Tissue nonspecific alkaline phosphatase 4.12. Phospho 1 phosphatase 4.13. Ectonucleotide pyrophosphatase/phosphodiesterase 4.14. Biological effects of hydroxyapatite on bone matrix proteins 4.15. Sclerostin 4.16. Tenascin C 4.17. Phosphate-regulating neutral endopeptidase (PHEX) 4.18. Matrix extracellular phosphoglycoprotein (MEPE, OF45) 4.19. Functional importance of proteolysis in activation of transglutaminase and PCOLCE 4.20. Neutral proteases in bone 5. Summary and Perspective 6. Acknowledgements 7. References 1. ABSTRACT The impact of genetics has dramatically affected nteractions which act in positive and negative ways to our understanding of the functions of non-collagenous regulate the process of bone mineralization. Several new proteins. Specifically, mutations and knockouts have examples from the author’s laboratory are provided defined their cellular spectrum of actions.
    [Show full text]
  • Chemical Properties Biological Description Solubility Information
    Data Sheet (Cat.No.T0947) Dexamethason acetate Chemical Properties CAS No.: 1177-87-3 Formula： C24H31FO6 Molecular Weight： 434.51 Appearance： Solid Storage： 0-4℃ for short term (days to weeks), or -20℃ for long term (months). Biological Description Description Dexamethasone Acetate is the acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. Targets(IC50) Annexin A1: None Glucocorticoid Receptor: None IL receptor: None iNOS: None In vitro Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. [1] Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. [2]Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. [3] Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. [5] In vivo Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2- acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]